238 related articles for article (PubMed ID: 28667675)
1. D-512, a novel dopamine D
Lindenbach D; Das B; Conti MM; Meadows SM; Dutta AK; Bishop C
Br J Pharmacol; 2017 Sep; 174(18):3058-3071. PubMed ID: 28667675
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
Reavill C; Boyfield I; Coldwell M; Nelson P
J Pharm Pharmacol; 2000 Sep; 52(9):1129-35. PubMed ID: 11045894
[TBL] [Abstract][Full Text] [Related]
4. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
[TBL] [Abstract][Full Text] [Related]
5. Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.
Das B; Vedachalam S; Luo D; Antonio T; Reith ME; Dutta AK
J Med Chem; 2015 Dec; 58(23):9179-95. PubMed ID: 26555041
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
8. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
9. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
[TBL] [Abstract][Full Text] [Related]
10. Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Ghosh B; Antonio T; Zhen J; Kharkar P; Reith ME; Dutta AK
J Med Chem; 2010 Feb; 53(3):1023-37. PubMed ID: 20038106
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.
Johnson M; Antonio T; Reith ME; Dutta AK
J Med Chem; 2012 Jun; 55(12):5826-40. PubMed ID: 22642365
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
14. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
Wang Y; Bouabid S; Darvas M; Zhou FM
Exp Neurol; 2020 Nov; 333():113427. PubMed ID: 32735872
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
16. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
17. Novel multifunctional dopamine D
Luo D; Sharma H; Yedlapudi D; Antonio T; Reith MEA; Dutta AK
Bioorg Med Chem; 2016 Nov; 24(21):5088-5102. PubMed ID: 27591013
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.
Rogers DC; Costall B; Domeney AM; Gerrard PA; Greener M; Kelly ME; Hagan JJ; Hunter AJ
Psychopharmacology (Berl); 2000 Jul; 151(1):91-7. PubMed ID: 10958122
[TBL] [Abstract][Full Text] [Related]
19. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
20. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
Millan MJ; Iob L; Péglion JL; Dekeyne A
Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
